PathAI logo

Behind the scenes: Dr. Andy Beck, PathAI CEO, talks PathExplore

Drug Discovery and Development


In a recent conversation with Dr. Andy Beck, co-founder and CEO of PathAI, we had the opportunity to discuss PathExplore, an AI-driven platform that aims to transform the way tumor microenvironment (TME) analysis is conducted. Traditional methods such as manual pathology, multiplex immunofluorescence and single-cell omics often face limitations, including high costs or tissue consumption. PathExplore addresses these challenges by using AI to analyze digitized H&E slides, which are widely available and don’t necessitate advanced assays or equipment.
Read More